The mechanism of action, pharmacokinetics, and clinical efficacy of carfilzomib for the treatment of multiple myeloma

Abstract

Introduction: The development of novel agents, such as immunomodulatory drugs and proteasome inhibitors, has led to a considerable increment in the response rate (RR) and outcomes for multiple myeloma (MM) patients. Unfortunately, MM patients will inevitably relapse and become resistant to new drugs. This led to the continuous development of novel agents. Carfilzomib is a second-generation proteasome inhibitor, demonstrating promising results in relapsed/refractory (RR) and newly diagnosed (ND) MM patients.

Areas covered: Herein, the authors review Phase I and II trials on carfilzomib for the treatment of MM. They also describe the profile of the drug during Phase I escalating doses and evaluate the efficacy of carfilzomib both alone and in combination. Finally, the authors also review and discuss the carfilzomib safety profile.

Expert opinion: Clinical trials (Phases I and II) with carfilzomib, used both as single agent or in combination with other therapies, established the maximum tolerated dose and recommended schedule of administration. Preliminary data showed that it had a high efficacy and a good safety profile both in RRMM and NDMM patients. Carfilzomib seems to be effective in patients previously treated with bortezomib. Future Phase II and III studies will better define the role of carfilzomib in the treatment of MM as well as its optimum dose.

Keywords::

• carfilzomib
• myeloma
• proteasome inhibitor
• therapy

Declaration of interest

A Palumbo has received consultancy fees and honoraria from Celgene, Janssen-Cilag, Millennium Pharmaceuticals, Onyx, Amgen, and Bristol-Myers Squibb. S Bringhen has received honoraria from Celgene, Janssen-Cilag, Novartis, and served on the advisory committee of Merck Sharp and Dohme. All other authors declare that they have no conflict of interest and have received no payment in the preparation of their manuscript.